

# Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial

**Giulia Magnani<sup>1</sup>, Robert F. Storey<sup>2</sup>, Gabriel Steg<sup>3,4,5</sup>, Deepak L. Bhatt<sup>1</sup>, Marc Cohen<sup>6</sup>, Julia Kuder<sup>1</sup>, Kyungah Im<sup>1</sup>, Philip Aylward<sup>7</sup>, Diego Ardissino<sup>8</sup>, Daniel Isaza<sup>9</sup>, Alexander Parkhomenko<sup>10</sup>, Assen R. Goudev<sup>11</sup>, Mikael Dellborg<sup>12</sup>, Frederic Kontry<sup>13</sup>, Ramon Corbalan<sup>14</sup>, Felix Medina<sup>15</sup>, Eva C. Jensen<sup>16</sup>, Peter Held<sup>16</sup>, Eugene Braunwald<sup>1</sup>, Marc S. Sabatine<sup>1</sup>, and Marc P. Bonaca<sup>1\*</sup>**

<sup>1</sup>TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, USA; <sup>2</sup>Department of Cardiovascular Science, University of Sheffield, Sheffield, UK; <sup>3</sup>Cardiology Department, DHU-FIRE, Hôpital Bichat, Paris, France; <sup>4</sup>Université Paris-Diderot, Paris, France; <sup>5</sup>INSERM U1148, Paris, France; <sup>6</sup>Cardiovascular Division, Department of Medicine, Rutgers-New Jersey Medical School, New York, USA; <sup>7</sup>Division of Medicine, Cardiac & Critical Care Services, Flinders University and Medical Centre, Adelaide, Australia; <sup>8</sup>Cardiovascular Division, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; <sup>9</sup>Fundación CardiolInfantil, Bogota, Colombia; <sup>10</sup>Ukrainian Strazhesko Institute of Cardiology, Kiev, Ukraine; <sup>11</sup>Department of Cardiology, Queen Giovanna University Hospital, Sofia, Bulgaria; <sup>12</sup>Department of Molecular and Clinical Medicine/Cardiology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>13</sup>Department of Cardiology, Stavanger University Hospital, Stavanger, Norway; <sup>14</sup>Cardiovascular Division, Pontificia Universidad Católica de Chile, Santiago, Chile; <sup>15</sup>Hospital Nacional Cayetano Heredia, San Martin de Porres, Lima, Peru; and <sup>16</sup>AstraZenecaAZ R&D, Molndal, Sweden

Received 24 July 2015; revised 20 August 2015; accepted 25 August 2015; online publish-ahead-of-print 6 October 2015

See page 409 for the editorial comment on this article (doi:10.1093/eurheartj/ehv471)

## Aims

We evaluated the relationship of renal function and ischaemic and bleeding risk as well as the efficacy and safety of ticagrelor in stable patients with prior myocardial infarction (MI).

## Methods and results

Patients with a history of MI 1–3 years prior from PEGASUS-TIMI 54 were stratified based on estimated glomerular filtration rate (eGFR), with  $<60$  mL/min/1.73 m<sup>2</sup> pre-specified for analysis of the effect of ticagrelor on the primary efficacy composite of cardiovascular death, MI, or stroke (major adverse cardiovascular events, MACE) and the primary safety endpoint of TIMI major bleeding. Of 20 898 patients, those with eGFR  $<60$  ( $N = 4849$ , 23.2%) had a greater risk of MACE at 3 years relative to those without, which remained significant after multivariable adjustment (hazard ratio, HR<sub>adj</sub> 1.54, 95% confidence interval, CI 1.27–1.85,  $P < 0.001$ ). The relative risk reduction in MACE with ticagrelor was similar in those with eGFR  $<60$  (ticagrelor pooled vs. placebo: HR 0.81; 95% CI 0.68–0.96) vs.  $\geq 60$  (HR 0.88; 95% CI 0.77–1.00,  $P_{\text{interaction}} = 0.44$ ). However, due to the greater absolute risk in the former group, the absolute risk reduction with ticagrelor was higher: 2.7 vs. 0.63%. Bleeding tended to occur more frequently in patients with renal dysfunction. The absolute increase in TIMI major bleeding with ticagrelor was similar in those with and without eGFR  $<60$  (1.19 vs. 1.43%), whereas the excess of minor bleeding tended to be more pronounced (1.93 vs. 0.69%).

## Conclusion

In patients with a history of MI, patients with renal dysfunction are at increased risk of MACE and consequently experience a particularly robust absolute risk reduction with long-term treatment with ticagrelor.

## Keywords

Ticagrelor • Myocardial infarction • Secondary prevention • Renal dysfunction

\* Corresponding author. Tel: +617 278 0145, Fax: +617 734 7329, Email: [mbonaca@partners.org](mailto:mbonaca@partners.org)

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com).

## Introduction

Nearly one-third of patients with ST segment elevation myocardial infarction (MI) and >40% of those with a non-ST segment elevation MI have concomitant renal dysfunction.<sup>1</sup> As the population ages and the prevalence of conditions associated with both cardiovascular (CV) risk and risk of renal dysfunction, such as diabetes, increases, the population with concomitant chronic ischaemic heart disease and renal dysfunction is anticipated to grow significantly.<sup>2,3</sup> The presence of renal dysfunction in patients who have an MI is associated with worse outcomes, with an inverse, graded association between estimated glomerular filtration rate (eGFR) and major adverse cardiovascular events (MACE).<sup>4</sup> The relationship between renal dysfunction and ischaemic risk is complex and may be caused by accelerated atherosclerosis, inflammation, oxidative stress, and a prothrombotic state.<sup>5</sup> In addition, renal function is a powerful integrator of several CV risk factors including age, hypertension, and diabetes. The impact of concomitant renal dysfunction in patients with prior MI is further complicated by its relationship with bleeding risk. Platelet dysfunction caused by defective activation, adhesion, and aggregation, compounded by an increased risk of overdosing with some antithrombotic drugs, results in an association between worsening renal function and bleeding.<sup>6</sup>

The benefit–risk of chronic antithrombotic therapies in patients with prior MI and concomitant renal dysfunction is therefore complex, with some studies suggesting that more intense platelets inhibition could be of less benefit,<sup>7,8</sup> whereas others suggest benefit of similar or even greater magnitude with those with reduced renal function.<sup>9–11</sup> Ticagrelor is a reversibly binding oral P2Y<sub>12</sub> receptor antagonist that provides more potent and less variable P2Y<sub>12</sub> inhibition compared with clopidogrel. Ticagrelor was shown to substantially reduce cardiovascular death, MI, or stroke (MACE) compared with clopidogrel in patients with acute coronary syndrome (ACS), with a consistent relative risk reduction in patients with and without renal dysfunction, but with an absolute risk reduction greater for patients with renal dysfunction.<sup>9</sup> In the PEGASUS-TIMI 54 trial, ticagrelor reduced MACE in stable outpatients with prior MI.<sup>12</sup> This reduction in ischaemic events was accompanied by an increase in Thrombolysis in Myocardial Infarction (TIMI) major bleeding. We therefore evaluated the relationship of ischaemic and bleeding risk with renal function and whether the efficacy and safety of ticagrelor was modified by the presence of renal dysfunction.

## Methods

### Study population

PEGASUS-TIMI 54 randomized patients with prior MI to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin. The design<sup>13</sup> and primary results of the trial have been published.<sup>12</sup> In brief, the trial enrolled 21 162 patients with a spontaneous MI occurring 1–3 years prior to enrolment and at least one of the following additional high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or chronic renal dysfunction, defined as a creatinine clearance <60 mL/min as estimated by the Cockcroft-Gault equation. Patients with end-stage renal failure requiring dialysis were excluded, but otherwise there was no restriction or dose adjustment for

renal function. Patients were ineligible if there was planned use of a P2Y<sub>12</sub> receptor antagonist or anticoagulant therapy during the study period; if they had a bleeding disorder or a history of an ischaemic stroke or intracranial bleeding, a central nervous system tumour, or an intracranial vascular abnormality; or if they had had gastrointestinal bleeding within the previous 6 months or major surgery within the previous month.

### Endpoints

The primary efficacy endpoint was the composite of CV death, MI, or stroke (MACE). The primary safety endpoint was TIMI major bleeding.<sup>13</sup> Additional safety endpoints were TIMI minor bleeding, intracranial haemorrhage (ICH), and fatal bleeding. A Clinical Events Committee blinded to treatment allocation adjudicated all efficacy and bleeding events. Adverse events were site reported and the subset of renal adverse events was predefined as a subset of adverse event preferred terms (see Supplementary material online, Table S1).

### Laboratory assessments and definition of renal dysfunction

Venous blood samples were obtained at randomization, during follow-up visits, and 14–28 days after the end of treatment. After centrifugation, serum was frozen at –20°C and sent for central laboratory analysis including measurement of serum creatinine. Estimated glomerular filtration rate was based on the abbreviated Modification of Diet in Renal Disease Study Group equation (MDRD).<sup>14</sup> In addition, a sensitivity analysis assessing ischaemic and bleeding risk by eGFR and the effect of treatment was also performed using the Chronic Kidney Disease Epidemiology collaboration (CKD-EPI)<sup>15</sup> formula.

Renal function was characterized two ways in evaluating the relationship with ischaemic and bleeding risk in the placebo group. First, eGFR was examined as a continuous variable and its relationships with MACE and bleeding were evaluated using cubic splines. Second, eGFR was divided into categories consistent with Kidney Disease Outcomes Quality Initiative of the National Kidney Foundation definition and classification of CKD.<sup>16</sup> Because there were few patients with eGFR <30 mL/min/1.73 m<sup>2</sup>, patients were divided into four groups: ≥90, 60 to <90, 45 to <60, and <45 mL/min/1.73 m<sup>2</sup>. In evaluating the efficacy and safety of ticagrelor compared with placebo, analyses were performed using a pre-specified eGFR cutpoint of 60.0 mL/min/1.73 m<sup>2</sup> with patients having a baseline eGFR <60 mL/min categorized as having renal dysfunction and those with eGFR ≥60 as having normal renal function.

### Statistical considerations

Baseline characteristics were summarized using medians and quartiles for continuous variables and frequencies and percentage for categorical variables. Differences were tested with the Wilcoxon rank-sum test for continuous variables and with the Pearson  $\chi^2$  test for categorical data. Cox proportional hazard models were used to assess the risk of MACE and bleeding across category of renal function and were adjusted for baseline clinical characteristics that differed significantly between patients with and without renal dysfunction (age, sex, hypertension, current smoker, diabetes, history of percutaneous coronary intervention, CABG, multivessel coronary disease, history of >1 prior MI, peripheral artery disease, stroke, heart failure, and type of index event). The associations between renal function and the hazard for the MACE and TIMI major bleeding were evaluated using cubic splines.<sup>17</sup> Analyses of the efficacy and safety of ticagrelor were not adjusted because treatment was randomized and therefore baseline characteristics and potential confounders were approximately balanced. Efficacy analyses were performed on an intention-to-treat basis with a sensitivity analysis to assess the impact of differences in drug discontinuation using an on-treatment analysis. Safety

analyses included all the patients who underwent randomization and with creatinine at baseline available who received at least one dose of study drug and included all the events occurring after receipt of the first dose and within 7 days of the last dose of study drug.

## Results

A baseline serum creatinine concentration was available in 20 898 patients (99% of the overall trial population), of whom 3251 (15.6%), 12 798 (61.2%), 3536 (16.9%), and 1313 (6.3%), had an eGFR  $\geq 90$ , 60 to  $<90$ , 45 to  $<60$ , and  $<45$  mL/min/1.73 m<sup>2</sup>, respectively (eGFR  $\geq 60$ ,  $N = 16\,049$ , 76.8%; eGFR  $<60$ ,  $N = 4849$ , 23.2%). Baseline characteristics by category of eGFR are shown in Table 1 and stratified at  $<60$  and  $\geq 60$  mL/min/1.73 m<sup>2</sup> in Supplementary material online, Table S2. Lower eGFR was associated with older age, female sex, and CV risk factors including hypertension and diabetes, and CV disease including a history of multiple prior MIs, peripheral artery disease, and heart failure.


## Baseline renal function and ischaemic risk

There was an inverse, graded relationship between category of eGFR and the risk of MACE through 3 years in the placebo arm as the eGFR dropped  $<60$  mL/min/1.73 m<sup>2</sup> ( $P$  for trend  $<0.0001$ , Figure 1A, see Supplementary material online, Table S3) with a consistent relationship for each of the individual components ( $P$  for trend  $\leq 0.001$  for CV death, for MI, and for stroke, see Supplementary material online, Figure S1A). After adjusting for baseline clinical differences, eGFR remained an independent predictor of ischaemic risk, especially when eGFR dropped  $<60$  mL/min/1.73 m<sup>2</sup> (Figure 1B, see Supplementary material online, Table S3). When dichotomized, patients with an eGFR  $<60$  mL/min/1.73 m<sup>2</sup> had an adjusted hazard ratio (HR) for MACE of 1.54 (95% confidence interval, CI 1.27–1.85,  $P < 0.001$ ). The adjusted risk across categories of eGFR remained significant for each of the components of the primary endpoint (see Supplementary material online, Figure S1B).

**Table 1** Baseline characteristics by estimated glomerular filtration rate (mL/min/1.73 m<sup>2</sup>)

Characteristic	eGFR (mL/min/1.73 m <sup>2</sup> )				P-value
	$\geq 90$ , $N = 3251$ , $n$ (%)	60 to $<90$ , $N = 12\,798$ , $n$ (%)	45 to $<60$ , $N = 3536$ , $n$ (%)	$<45$ , $N = 1313$ , $n$ (%)	
eGFR, median (IQR)	97.7 (93.3, 105.4)	74.1 (67.5, 81.0)	54.2 (50.6, 57.4)	38.8 (33.3, 42.3)	n.a.
Demographics					
Age (years), median (IQR)	60 (55, 66)	65 (59, 70)	69 (64, 75)	72 (66, 78)	$<0.0001$
Female	478 (14.7)	2736 (21.4)	1198 (33.9)	580 (44.2)	$<0.0001$
BMI (kg/m <sup>2</sup> ), median (IQR)	27.7 (24.7, 31.0)	27.8 (25.2, 31.1)	27.9 (25.3, 31.3)	28.4 (25.3, 32.0)	$<0.0001$
Clinical characteristics					
Hypertension	2430 (74.8)	9607 (75.1)	2973 (84.1)	1185 (90.3)	$<0.0001$
Hypercholesterolaemia	2443 (75.2)	9908 (77.4)	2705 (76.5)	998 (76.0)	0.04
Current smoker	851 (26.2)	2125 (16.6)	400 (11.3)	122 (9.3)	$<0.0001$
Diabetes mellitus	1246 (38.3)	3732 (29.2)	1157 (32.7)	581 (44.3)	$<0.0001$
Multivessel coronary disease	2112 (65.0)	7655 (59.8)	1915 (54.2)	715 (54.5)	$<0.0001$
History of PCI	2800 (86.1)	10 776 (84.2)	2792 (79.0)	979 (74.6)	$<0.0001$
History of CABG	101 (3.1)	511 (4.0)	228 (6.5)	118 (9.0)	$<0.0001$
History of $>1$ prior MI	505 (15.5)	2037 (15.9)	617 (17.5)	296 (22.5)	$<0.0001$
Peripheral artery disease	178 (5.5)	595 (4.7)	223 (6.3)	132 (10.1)	$<0.0001$
History of stroke	10 (0.3)	50 (0.4)	21 (0.6)	14 (1.1)	0.002
History of HF	487 (15.0)	2375 (18.6)	875 (24.8)	451 (34.4)	$<0.0001$
Qualifying event					
Years from MI, median (IQR)	1.7 (1.2, 2.3)	1.7 (1.2, 2.3)	1.7 (1.3, 2.3)	1.7 (1.2, 2.4)	0.20
STEMI	1831 (56.4)	7005 (54.8)	1767 (50.0)	590 (45.1)	$<0.0001$
NSTEMI	1236 (38.1)	5068 (39.6)	1543 (43.7)	624 (47.7)	$<0.0001$
MI type unknown	181 (5.6)	713 (5.6)	221 (6.3)	95 (7.3)	$<0.0001$
Medications at enrolment					
Aspirin	3247 (99.9)	12 779 (99.9)	3534 (99.9)	1311 (99.9)	0.60
$\beta$ -Blocker	2641 (81.2)	10 525 (82.2)	2973 (84.1)	1120 (85.3)	0.0006
ACEI or ARB	2604 (80.1)	10 219 (79.9)	2923 (82.7)	1070 (81.5)	0.002


eGFR, estimated glomerular filtration rate;  $N$ , total number; IQR, interquartile range; BMI, body mass index; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; HF, heart failure; MI, myocardial infarction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction.



**Figure 1** KM curves for the primary endpoint of cardiovascular death, myocardial infarction, or stroke by eGFR (mL/min/1.73 m<sup>2</sup>) (A) and multi-variable-adjusted spline curves for the HR of the primary endpoint vs. estimated glomerular filtration rate modeled as a continuous variable (B). Placebo group only. Patients stratified into four groups (eGFR ≥ 90 mL/min/1.73 m<sup>2</sup>, 60 to < 90 mL/min/1.73 m<sup>2</sup>, 45 to < 60 mL/min/1.73 m<sup>2</sup>, and < 45 mL/min/1.73 m<sup>2</sup>). In B, the dotted lines represent the 95% pointwise confidence band. The reference value 98 is the median eGFR in the ≥ 90 group from the overall population. Cox proportional hazard models adjusted for baseline clinical characteristics that differed significantly between patients with and without renal dysfunction (age, sex, hypertension, current smoker, diabetes, history of percutaneous coronary intervention, CABG, multivessel coronary disease, history of more than one prior MI, peripheral artery disease, stroke, heart failure, and type of index event). eGFR, estimated glomerular filtration rate; yr, year; KM, Kaplan-Meier; N, total number; Adj., adjusted; HR, hazard ratio; CI, confidence interval.

The relationship between eGFR and ischaemic risk was very similar when eGFR was calculated using CKD-EPI instead (correlation coefficient between eGFR calculated with MDRD and

CKD-EPI 0.99, *P* < 0.0001) and was similar in those randomized to placebo only or all treatment arms pooled (see Supplementary material online, *Figure S2*).



**Figure 2** Bleeding risk by estimated glomerular filtration rate (mL/min/1.73 m<sup>2</sup>) (A) and multivariable-adjusted spline curves for the HR of the main efficacy endpoint vs. estimated glomerular filtration rate modeled as a continuous variable (B). Placebo group only. Patients stratified into four groups (eGFR  $\geq 90$  mL/min/1.73 m<sup>2</sup>, 60 to <90 mL/min/1.73 m<sup>2</sup>, 45 to <60 mL/min/1.73 m<sup>2</sup>, and <45 mL/min/1.73 m<sup>2</sup>). Cox proportional hazard models adjusted for baseline characteristics that differed significantly between patients with and without renal dysfunction (age, sex, hypertension, current smoker, diabetes, history of percutaneous coronary intervention, CABG, multivessel coronary disease, history of more than one prior MI, peripheral artery disease, stroke, heart failure, and type of index event). eGFR, estimated glomerular filtration rate; yr, year; KM, Kaplan-Meier; N, total number; Adj., adjusted; HR, hazard ratio; CI, confidence interval; ICH, intracranial haemorrhage; TIMI, Thrombolysis in Myocardial Infarction. The dotted lines represent the 95% pointwise confidence band. The reference value 98 is the median eGFR in the  $\geq 90$  group from overall population.

### Baseline renal function and bleeding risk

There were trends across categories of lower eGFR for increased rates of TIMI major bleeding, TIMI minor bleeding, and ICH or fatal bleeding in the placebo arm (Figure 2A, see Supplementary material

online, Table S3). After adjusting for baseline differences, there was no longer an appreciable relationship between eGFR and TIMI major bleeding (Figure 2B), but there was for minor bleeding, Supplementary material online, Figure S3 and Table S3). When

dichotomizing eGFR at 60 mL/min/1.73 m<sup>2</sup>, the adjusted HR for TIMI major bleeding for those with eGFR <60 relative to those with eGFR ≥60 was 1.19 (95% CI 0.64–2.24, *P* = 0.58) and the adjusted HR for TIMI minor bleeding was 3.02 (95% CI 1.07–8.48, *P* = 0.04). The relationship between eGFR and bleeding was similar in those randomized to placebo only or all treatment arms pooled (see Supplementary material online, Figure S2).

### Efficacy of ticagrelor in patients with renal dysfunction


The relative risk reduction in MACE achieved with ticagrelor (doses pooled) was similar in patients with renal dysfunction (eGFR <60 mL/min/1.73 m<sup>2</sup>, *n* = 4849; HR 0.81; 95% CI 0.68–0.96) compared with those without (eGFR ≥60 mL/min/1.73 m<sup>2</sup>, *n* = 16 049; HR 0.88; 95% CI 0.77–1.00, *P*-interaction = 0.44, Figure 3) and similar when eGFR was modeled as a continuous variable (see Supplementary material online, Figure S4). However, given the greater risk of MACE in patients with renal dysfunction, the respective absolute risk reduction in MACE at 3 years was four times higher in that group: 2.70% (95% CI 0.49–4.93) vs. 0.63% (95% CI -0.32–1.57). The pattern of efficacy was largely consistent with the individual doses and the individual components of the primary endpoint (see Supplementary material online, Figure S5). Results were consistent regardless of whether eGFR was calculated using MDRD or CKD-EPI (see Supplementary material online, Table S4). The rate of death from any cause did not differ significantly with either dose of ticagrelor when compared with placebo, regardless renal function (see Supplementary material online, Table S5).

### Safety of ticagrelor in patients with renal dysfunction

The relative risk of TIMI major bleeding with ticagrelor was similar in those with and without renal dysfunction (ticagrelor pooled vs. placebo, eGFR <60: HR 1.98; 95% CI 1.13–3.46; eGFR ≥60: HR, 2.65; 95% CI 1.87–3.76; *P*<sub>interaction</sub> = 0.38, Table 2, see Supplementary material online, Figure S6). Likewise, the absolute risk of TIMI major bleeding with ticagrelor (pooled) was similar across eGFR category (1.19%, 95% CI 0.21–2.16 for those with eGFR <60 and 1.42%, 95% CI 0.92–1.91 for those with eGFR ≥60). The relative risk of TIMI minor bleeding was also increased consistently with ticagrelor regardless of renal function (*P*<sub>interaction</sub> = 0.98 for ticagrelor pooled); however, the absolute increase was higher in those with eGFR <60 (1.93%, 95% CI 1.05–2.81) compared with those with eGFR ≥60 (0.68%, 95% CI 0.42–0.95). The combination of ICH or fatal bleeding was not significantly increased with ticagrelor regardless of renal function. Results were consistent regardless of whether eGFR was calculated using MDRD or CKD-EPI (see Supplementary material online, Table S4).

### Other safety events and tolerability

In the placebo arm, renal adverse events were more frequent in patients with an eGFR <60 compared with those with an eGFR ≥60 (8.53 vs. 1.23%, HR<sub>adj</sub> 7.14, 95% CI 5.00–10.0, *P* < 0.001). However, ticagrelor did not increase the risk of renal adverse events overall and there was no statistical heterogeneity by eGFR category (*P*<sub>interaction</sub> = 0.22, see Supplementary material online, Table S6). Likewise, gout occurred more frequently in patients with an eGFR



**Figure 3** Kaplan–Meier estimated occurrence of CV death, MI, or stroke by estimated glomerular filtration rate. Kaplan–Meier rates of primary endpoints through 3 years, according to the study group and by an eGFR cut-point of 60 mL/min/1.73 m<sup>2</sup>. *P* for interaction = 0.44. eGFR, estimated glomerular filtration rate; yr, year; KM, Kaplan–Meier; HR, hazard ratio; CI, confidence interval; ARR, absolute risk reduction.

**Table 2** Safety endpoints at 3 years by estimated glomerular filtration rate (mL/min/1.73 m<sup>2</sup>)

Endpoint	eGFR	% 3-year KM	Ticagrelor pooled		P-int	Ticagrelor 90 vs. placebo HR (95% CI)		P-int	Ticagrelor 60 vs. placebo HR (95% CI)		P-int
			Ticagrelor 90	Ticagrelor 60		Placebo	Ticagrelor 60				
Bleeding											
TIMI major	≥60	2.41	2.74	2.09	0.99	2.65 (1.87–3.76)	0.38	3.05 (2.10–4.43)	0.11	2.29 (1.56–3.36)	0.998
	<60	2.53	2.13	2.94	1.34	1.98 (1.13–3.46)		1.69 (0.89–3.19)		2.29 (1.25–4.19)	
TIMI minor	≥60	0.89	0.95	0.84	0.21	4.05 (2.02–8.12)	0.98	4.51 (2.17–9.37)	0.95	3.63 (1.73–7.62)	0.997
	<60	2.62	2.65	2.59	0.69	4.00 (1.90–8.40)		4.36 (2.00–9.51)		3.62 (1.62–8.05)	
ICH or fatal	≥60	0.64	0.65	0.62	0.52	1.38 (0.81–2.86)	0.27	1.50 (0.72–2.51)	0.15	1.28 (0.70–2.35)	0.65
	<60	0.79	0.60	0.98	0.95	0.82 (0.38–2.78)		0.64 (0.24–2.74)		1.00 (0.42–2.43)	

eGFR, estimated glomerular filtration rate; KM, Kaplan–Meier; HR, hazard ratio; CI, confidence interval; TIMI, thrombolysis in myocardial infarction; ICH, intracranial haemorrhage.

<60 (HR<sub>adj</sub> 3.62, 95% CI 2.21–5.94,  $P < 0.001$ ), but the relative risk of gout with ticagrelor was, if anything, less pronounced in those with renal dysfunction (see Supplementary material online, Table S6). In patients randomized to placebo, there was a non-significant increase of dyspnoea events in patients with an eGFR <60 compared with those with an eGFR ≥60 (7.5 vs. 6.0%, HR<sub>adj</sub> 1.18, 95% CI 0.92–1.51,  $P = 0.19$ ). Both ticagrelor doses increased dyspnoea events, compared with placebo, regardless of renal function (see Supplementary material online, Table S6). In the placebo arm, premature permanent drug discontinuation was higher in those with an eGFR <60 compared those with an eGFR ≥60 (28.9 vs. 20.9%, HR<sub>adj</sub> 1.27, 95% CI 1.12–1.43,  $P < 0.001$ ). Similarly, rates of premature permanent drug discontinuation were higher in the ticagrelor arms in those with renal dysfunction (see Supplementary material online, Table S6). Because permanent drug discontinuation was higher in those with renal dysfunction, a sensitivity analysis exploring the magnitude of efficacy in patients on treatment was performed in patients stratified by eGFR. A more marked relative risk reduction with ticagrelor was observed, particularly in those with renal dysfunction (HR 0.72, 95% CI 0.59–0.89, for eGFR <60; HR 0.83, 95% CI 0.72–0.96, for eGFR ≥60).

## Discussion

In stable outpatients with prior MI randomized in the PEGASUS-TIMI 54 trial, worse renal function was an independent predictor of MACE. The relative risk reduction in MACE with ticagrelor was similar regardless of renal function. However, due to their higher ischaemic risk, patients with renal dysfunction, who constituted approximately one-quarter of the trial population, experienced a greater absolute risk reduction in MACE when treated with ticagrelor.

Previous studies have described an inverse relationship between eGFR and ischaemic and bleeding events in patients with a recent MI.<sup>4,9,18</sup> The current study builds on these observations but now extends it to stable outpatients who were on average 1.7 years out from their qualifying MI and who were observed for a median of 33 months. It is notable that the rate for MACE was ~14% at 3 years in those with renal dysfunction, which was double that for those with normal renal function, making renal dysfunction a useful clinical indicator of heightened ischaemic risk. Moreover, this risk was independent of other clinical characteristics. Bleeding risk also tended to increase with renal dysfunction. However, after multivariable adjustment, this relationship only persisted for TIMI minor bleeding. While these findings were most pronounced for patients with an eGFR <60 ( $N = 4849$ , 23%), it is notable that only a small proportion of patients in the trial ( $N = 3251$ , 15%) had normal renal function (i.e. eGFR ≥90) and more than half ( $N = 12\,798$ , 60%) had slightly reduced renal function (eGFR 60 to <90). Although chronic non-end-stage renal dysfunction was an enrichment criteria in the trial, the prevalence of patients with CKD we observed is in line with previous epidemiologic observations.<sup>1,4</sup>

The relative risk reduction in MACE with ticagrelor tended to be slightly greater in patients with renal dysfunction (19 vs. 12%), but the difference was not statistically significant. Importantly, however, the greater rate of ischaemic events in patients with renal dysfunction translated into a greater absolute risk reduction with ticagrelor in these patients. Specifically, the absolute risk reduction in MACE

with ticagrelor was 2.7%, translating into a number needed to treat of 37 to prevent one MACE event even when initiated in the stable setting. This robust risk reduction occurred in spite of higher rates of drug discontinuation, with on-treatment analyses showing an even greater magnitude of benefit.

These efficacy findings are corroborated by observations for ticagrelor in the setting of ACS, where there also tended to be a greater relative risk reduction and there was a fourfold greater absolute risk reduction in MACE in patients with renal dysfunction.<sup>9</sup> When integrating the findings from both datasets, patients with ACS and renal dysfunction enjoy a robust absolute risk reduction with ticagrelor which continues into the stable phase as long-term secondary prevention.

Both the relative and absolute increased risk of TIMI major bleeding with ticagrelor were similar for patients with and without renal dysfunction. However, the absolute excess of TIMI minor bleeding (haemoglobin drop between 3 and 5 g/dL) with ticagrelor was greater in those with renal dysfunction. There was no relative or absolute increase in ICH or fatal bleeding with ticagrelor overall or in those with and without renal dysfunction. Consistent with findings from other large trials with ticagrelor, there was no increase in renal adverse events with ticagrelor in the current trial. Gout was more frequent in patients with renal dysfunction and was increased with ticagrelor to a similar extent regardless of eGFR.

## Limitations

There are limitations to the current study. First, although pre-specified, our observations are based on subgroups in the overall trial. Importantly, there were significant baseline differences between those with and without renal dysfunction. CKD was an enrichment factor in the PEGASUS-TIMI 54 trial and non-CKD patients could have been enriched with atherothrombotic risk factors other than CKD, an observation that differs from clinical practice where patients with CKD have more comorbidities compared with patients without CKD.<sup>3</sup> Although when evaluating the relationship of MACE and bleeding with renal function, we adjusted for these differences by multivariable analysis, some residual confounding may remain. Given that PEGASUS-TIMI 54 was a randomized trial, these differences were balanced between the two ticagrelor groups and placebo group and thus not expected to influence the treatment comparison. In addition, there were a relatively small number of patients with severe renal dysfunction and patients requiring dialysis were excluded from the trial. Our analyses were based on eGFR calculated using the MDRD equation using baseline serum creatinine. However, the PEGASUS-TIMI 54 trial enrolled a stable population and therefore it is unlikely that there would be large fluctuations of creatinine values from baseline, as might be observed in an acute population.

## Conclusion

In stable patients with a history of MI, renal dysfunction was independently associated with an increased risk of MACE. Although the relative risk reduction in MACE with ticagrelor was similar regardless of renal function, due to their higher ischaemic risk, patients with renal dysfunction experienced a greater absolute risk reduction in MACE when treated with ticagrelor. These findings have

important treatment implications for the large and growing proportion of patients with coronary disease and concomitant renal dysfunction.

## Authors' contributions

G.M., E.B., M.S.S., and M.P.B.: conceived and designed the research; PEGASUS-TIMI 54 Investigators: acquired the data; J.K. and K.I.: performed statistical analysis; G.M. and M.P.B.: drafted the manuscript; All authors made critical revision of the manuscript for key intellectual content M.S.S. and E.B.: handled funding and supervision.

## Supplementary material

Supplementary material is available at *European Heart Journal* online.

## Funding

This study was supported by a grant from AstraZeneca.

**Conflict of interest:** G.M. reports grants from AstraZeneca, during the conduct of the study. R.F.S. reports grants and personal fees from AstraZeneca, during the conduct of the study; grants, personal fees and other from AstraZeneca, personal fees from Aspen, personal fees from PlaqueTec, personal fees from The Medicines Company, personal fees from ThermoFisher Scientific, grants and personal fees from Merck, personal fees from Correio, personal fees from Roche, personal fees from Regeneron, personal fees from Sanofi Aventis, personal fees and non-financial support from Accumetrics, personal fees from Daiichi Sankyo/Eli Lilly, outside the submitted work. In addition, R.F.S. has a patent Related to study results pending. G.S. reports personal fees from the TIMI Study Group, during the conduct of the study; personal fees from Amarin, personal fees from AstraZeneca, personal fees from Bayer, personal fees from Boehringer-Ingelheim, personal fees from Bristol-Myers-Squibb, personal fees from Daiichi-Sankyo, personal fees from GlaxoSmithKline, personal fees from Lilly, personal fees from Merck-Sharp-Dohme, personal fees from Novartis, personal fees from Otsuka, personal fees from Pfizer, personal fees from Roche, personal fees from Medtronic, grants and personal fees from Sanofi, grants and personal fees from Servier, personal fees from Vivus, personal fees from Janssen, personal fees and non-financial support from The Medicines Company, personal fees from Orexigen, personal fees from Regado, outside the submitted work. D.L.B. discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Get With The Guidelines Steering Committee; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor); Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Site Co-Investigator:

Biotronik, St. Jude Medical; Trustee: American College of Cardiology; Unfunded Research: FlowCo, PLx Pharma, Takeda. M.C. reports personal fees from Astra Zeneca during the conduction of the study; personal fees from Lilly, personal fees from Janssen, personal fees from Merck, outside the submitted work. M.G. reports modest speakers honoraria from Merck, AstraZeneca, Servier. Advisory board: modest fees from Merck, AstraZeneca, Pfizer, Amgen. R.C.: Participation in Advisory Boards for Astra Zeneca. E.C.J.: AstraZeneca employee. P.H.: AstraZeneca employee. E.B. reports grants (through the Brigham and Women's Hospital) from AstraZeneca, Daiichi-Sankyo, Merck & Co, and Glaxo Smith Kline; personal fees for consultancies from Genzyme, Medicines Co, Theravance, and Sanofi-Aventis; honoraria for lectures from Daiichi-Sankyo, Menarini and Medscape. M.S.S. reports grants (through Brigham and Women's Hospital) from Abbott Laboratories, Accumetrics, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Critical Diagnostics, Daiichi-Sankyo, Eisai, Genzyme, Gilead, GlaxoSmithKline, Intarcia, Merck, Nanosphere, Roche Diagnostics, Sanofi-aventis, and Takeda, personal fees from Aegerion, Alnylam, Amgen, AstraZeneca, Bristol-Myers Squibb, Cubist, CVS Caremark, Intarcia, Merck, MyoKardia, Pfizer, Quest Diagnostics, Sanofi-aventis, Vertex, and Zeus Scientific. M.P.B. reports personal fee from AstraZeneca, Merck, Bayer, and Roche Diagnostics.

## References

1. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010;**121**:357–365.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. *JAMA* 2007;**298**:2038–2047.
3. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K, BhattDL; REACH Registry Investigators. Renal function, atherothrombosis extent, and outcomes in high-risk patients. *Am Heart J* 2009;**158**:141–148.
4. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. *N Engl J Med* 2004;**351**:1285–1295.
5. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS; The Hemodialysis (HEMO) Study. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int* 2000;**58**:353–362.
6. Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. *Circulation* 2012;**125**:2649–2661.
7. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczec LA, Califf RM, Topol EJ. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. *Am Heart J* 2008;**155**:687–693.
8. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial). *Am J Cardiol* 2009;**103**:1359–1363.
9. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. *Circulation* 2010;**122**:1056–1067.
10. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:2999–3054.
11. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2012;**33**:2569–2619.
12. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med* 2015;**372**:1791–1800.
13. Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. *Am Heart J* 2014;**167**:437–444.
14. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. *Clin Chem* 2007;**53**:766–772.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;**150**:604–612.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;**39**(Suppl. 1):S1–S266.
17. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. *Comput Methods Programs Biomed* 1997;**54**:201–208.
18. Vasaiwala S, Cannon CP, Fonarow GC, Peacock WF, Laskey W, Schwamm LH, Liang L, Hernandez AF, Peterson ED, Rosas SE, Bhatt DL; Get with the Guidelines Steering Committee and Investigators. Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program. *Clin Cardiol* 2012;**35**:541–547.